首页> 美国卫生研究院文献>Frontiers in Pharmacology >A Comprehensive Strategy to Evaluate Compatible Stability of Chinese Medicine Injection and Infusion Solutions Based on Chemical Analysis and Bioactivity Assay
【2h】

A Comprehensive Strategy to Evaluate Compatible Stability of Chinese Medicine Injection and Infusion Solutions Based on Chemical Analysis and Bioactivity Assay

机译:基于化学分析和生物活性分析的中药注射液溶液相容性评价综合策略

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Stability of traditional Chinese medicine injection (TCMI) is an important issue related with its clinical application. TCMI is composed of multi-components, therefore, when evaluating TCMI stability, several marker compounds cannot represent global components or biological activities of TCMI. Till now, when evaluating TCMI stability, method involving the global components or biological activities has not been reported. In this paper, we established a comprehensive strategy composed of three different methods to evaluate the chemical and biological stability of a typical TCMI, Danhong injection (DHI). UHPLC-TQ/MS was used to analyze the stability of marker compounds (SaA, SaB, RA, DSS, PA, CA, and SG) in DHI, UHPLC-QTOF/MS was used to analyze the stability of global components (MW 80–1000 Da) in DHI, and cell based antioxidant capability assay was used to evaluate the bioactivity of DHI. We applied this strategy to assess the compatible stability of DHI and six infusion solutions (GS, NS, GNS, FI, XI, and DGI), which were commonly used in combination with DHI in clinic. GS was the best infusion solution for DHI, and DGI was the worst one based on marker compounds analysis. Based on global components analysis, XI and DGI were the worst infusion solutions for DHI. And based on bioactivity assay, GS was the best infusion solution for DHI, and XI was the worst one. In conclusion, as evaluated by the established comprehensive strategy, GS was the best infusion solution, however, XI and DGI were the worst infusion solutions for DHI. In the compatibility of DHI and XI or DGI, salvianolic acids in DHI would be degraded, resulting in the reduction of original composition and generation of new components, and leading to the changes of biological activities. This is the essence of instability compatibility of DHI and some infusion solutions. Our study provided references for choosing the reasonable infusion solutions for DHI, which could contribute the improvement of safety and efficacy of DHI. Moreover, the established strategy may be applied for the compatible stability evaluation of other TCMIs.
机译:中药注射剂(TCMI)的稳定性是与其临床应用相关的重要问题。 TCMI由多种成分组成,因此,在评估TCMI稳定性时,几种标记物不能代表TCMI的整体成分或生物活性。到目前为止,在评估TCMI稳定性时,尚未报道涉及全球成分或生物活性的方法。在本文中,我们建立了由三种不同方法组成的综合策略,以评估典型TCMI丹红注射液(DHI)的化学和生物稳定性。 UHPLC-TQ / MS用于分析DHI中标记化合物(SaA,SaB,RA,DSS,PA,CA和SG)的稳定性,UHPLC-QTOF / MS用于分析整体组分的稳定性(MW 80 DHI中––1000 Da),并使用基于细胞的抗氧化能力测定来评估DHI的生物活性。我们应用该策略评估了DHI和六种输注溶液(GS,NS,GNS,FI,XI和DGI)的相容性稳定性,这些溶液在临床上通常与DHI结合使用。根据标记物化合物分析,GS是DHI最好的输液,而DGI是最差的。根据全球成分分析,XI和DGI是DHI最差的输液解决方案。根据生物活性测定,GS是DHI的最佳输液,而XI是最差的输液。总而言之,按照既定的综合策略评估,GS是最佳的输液方案,而XI和DGI是DHI的最差输液方案。在DHI与XI或DGI的相容性中,DHI中的丹酚酸将被降解,从而导致原始成分的减少和新成分的产生,并导致生物活性的变化。这是DHI和某些输液解决方案不稳定兼容性的本质。我们的研究为选择合理的DHI输液提供了参考,可以为DHI的安全性和有效性的改善做出贡献。而且,所建立的策略可以用于其他TCMI的兼容性稳定性评估。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号